-
Coherus BioSciences Inc. NASDAQ:CHRS Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients' lives and to deliver significant savings to the health care system.
Location: 333 Twin Dolphin Dr Ste 600, California, 94065-1442, US | Website: www.coherus.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
347.3M
Cash
97.69M
Avg Qtr Burn
-15.5M
Short % of Float
29.74%
Insider Ownership
1.38%
Institutional Own.
70.31%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CIMERLI (CHS-201) (Lucentis biosimilar) Details Wet age-related macular degeneration , Age-related macular degeneration, Eye disease | Approved Quarterly sales | |
YUSIMRY (CHS-1420) (Humira® Biosimilar (adalimumab)) (Anti-TNF) Details Arthritis, Psoriasis, Inflammatory disease | Approved Quarterly sales | |
LOQTORZI (Toripalimab) + Chemotherapy Details Nasopharyngeal carcinoma | Approved Quarterly sales | |
UDENYCA® (pegfilgrastim-cbqv) Biosimilar Details Cancer, Chemotherapy-induced neutropenia | Approved Quarterly sales | |
UDENYCA® ONBODY Details Cancer, Chemotherapy-induced neutropenia | Approved Quarterly sales | |
Toripalimab (anti-PD-1 antibody)(JUPITER-06) + Chemotherapy Details Esophageal Squamous Cell Carcinoma | Phase 3 Update | |
LOQTORZI (Toripalimab) + INO 3112 Details HPV+ oropharyngeal cancer, Cancer | Phase 3 Initiation | |
Casdozokitug (casdozo) w/ atezolizumab & bevacizumab Details Cancer, Hepatocellular carcinoma | Phase 2 Data readout | |
Toripalimab +/- CHS-006 (anti-TIGIT) (anti-PD-1) Details Non-small cell lung carcinoma, Hepatocellular carcinoma, Solid tumor/s | Phase 1/2 Data readout | |
Casdozokitug (casdozo) Details Cancer, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
CHS-114 (SRF114) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
CHS-131 Details Multiple sclerosis, Non-alcoholic steatohepatitis | Failed Discontinued | |
Toripalimab (CHS-305) Biosimilar (bevacizumab) + Chemotherapy Details Cancer, Small cell lung cancer | Failed Discontinued | |
Toripalimab (CHS-305) Biosimilar (bevacizumab) + anti-TIGIT Details Non-small cell lung carcinoma, Cancer | Failed Discontinued |